Recruiting

Adenosine

Sponsor:

Weill Medical College of Cornell University

Code:

NCT03218137

Conditions

Premature Ventricular Contraction (PVC)

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Accepted

Interventions

Adenosine

Study Details

Brief summary:

Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and/or verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.

Conditions

Premature Ventricular Contraction (PVC)

Study ID

NCT03218137

Start date

Feb 13, 2017

Status verified date

Jun, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Diagnosis of premature ventricular contractions (PVCs)
  • Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs
  • Male or female between the ages of 18 and 70 years
  • Capable of giving informed consent

Exclusion Criteria:

  • Any structural heart disease
  • Coronary artery disease (≥ 70% stenosis)
  • Current treatment with anti-arrhythmic drugs
  • Pregnant
  • Asthma (if administering adenosine)

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

other: Adenosine/ Verapamil Arm

Adenosine: 0.84 mg/kg IV (140 mcg/kg/minute IV for 6 minutes) Verapamil: 0.15 mg/kg IV

Adenosine is known to terminate ventricular arrhythmias that are due to triggered activity (ref Lerman). To study the effects of adenosine on PVC, the investigators will administer Verapamil to slow down the heart initially and adenosine after catheters are introduced to patients who are being treated for symptomatic PVC and have consented to treatment with an invasive electrophysiology study and catheter ablation.

Interventions

Adenosine

Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg

Primary outcome measure

  • Effects of Adenosine on premature ventricular contractions (PVCs) as measured by EKG; [ Time Frame: baseline ]
  • Effects of verapamil on premature ventricular contractions (PVCs) as measured by EKGs. [ Time Frame: baseline ]

Central Contacts and Locations

Central contacts

James E Ip, M.D

212 746 2158jei9008@med.cornell.edu

Dolores T Reynolds, BSN

212 746 4617dtr2001@med.cornell.edu

Locations

Weill Cornell Medicine

Recruiting

New York, New York, United States, 10065

Contacts

Dolores T Reynolds, BSN

212 746 4617dtr2001@med.cornell.edu

James E Ip, M.D

212 746 2158jei9008@med.cornell.edu

More Information

Sponsor

Weill Medical College of Cornell University

Last update posted

Jun 23, 2026

Last verified

Jun, 2026

Keywords

  • Subjects
  • diagnosed

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Weill Medical College of Cornell University on 2026-06-23.